(Circulation. 1999;100:II-392.)
© 1999 American Heart Association, Inc.
Myocardial Protection and Vascular Biology |
The Role of Gene Therapy for Intimal Hyperplasia of Bypass Grafts
From the Division of Thoracic and Cardiovascular Surgery (D.G.C., J.A.C., R.C.D., J.A.D., C.J.M., T.A.O., H.V.S.), the Division of Endocrinology, Metabolism, Nutrition, and Internal Medicine (T.O.), and the Division of Cardiovascular Diseases and Internal Medicine (N.C., R.D.S.), Mayo Clinic and Mayo Foundation, Rochester, Minn.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Proliferation of the intima is an early lesion of saphenous vein graft disease. Early patency rates of radial artery grafts are acceptable, but little is known about their risk of intimal hyperplasia.
Methods and Results—To develop a model of intimal hyperplasia, we incubated human saphenous veins, internal mammary arteries, and radial arteries (n=6, 8, and 10, respectively) in an organ culture with Rosewell Park Memorial Institute 1640 (30% serum) for 0, 4, 7, 10, and 14 days. Quantitative histological studies were performed, and the average intimal-to-medial (I/M) ratio was calculated for each incubation interval. After 10 and 14 days of culture, the I/M ratio increased in the saphenous veins (P=0.03, P=0.04 versus 0 day, respectively). No significant increase occurred in the I/M ratio in either the internal mammary or radial arteries. Next, the ability of adenoviral gene transfers to inhibit intimal hyperplasia in the saphenous veins was evaluated. Adenoviral-mediated gene transfer of nitric oxide synthase significantly reduced the I/M ratio at 14 days compared with vehicle (P=0.001) and virus (P=0.004) controls.
Conclusions—The human saphenous vein has a greater propensity for intimal hyperplasia than arterial grafts; the human radial artery behaves similarly to the internal mammary artery. In the future, gene therapy may augment nitric oxide synthase, limiting vein graft disease.
Key Words: gene transfer • mammary arteries • nitric oxide • organ culture • radial artery • saphenous vein
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Compared with saphenous vein (SV) grafts, internal mammary artery (IMA) grafts to the left anterior descending coronary artery improve the survival of patients with multivessel disease; this improved outcome correlates with better long-term patency.1 Recently, there has been renewed interest in the radial artery (RA) for coronary artery bypass in the hope that it will expand the range of arterial grafts for surgical revascularization.2 However, the long-term patency of RA conduits will not be known for nearly a decade, and little information is available about the biological behavior of these bypass conduits in regard to early thrombosis and the development of intimal hyperplasia and atherosclerosis.
The SV is the most commonly used conduit for coronary surgery, but despite improvements in methods of harvest, preservation, and early antithrombotic therapy, 12% to 27% of vein grafts become occluded in the first year, one-half of which are within the first month.2 3 The subsequent annual occlusive rate is 2% to 4%.4 More than 10% of patients who have coronary artery bypass with only the SV require reoperation within 10 to 12 years,5 and repeat operations represent 10% to 30% of coronary surgery in the United States.6
The purpose of the present study was to evaluate the potential of the human SV, IMA, and RA to generate intimal hyperplasia in an extended organ culture. After the propensity of the vein graft for hyperplasia was confirmed, the study evaluated the ability of adenoviral-mediated gene transfer of bovine endothelial nitric oxide synthase (eNOS) to inhibit this process.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The Institutional Review Board of the Mayo Foundation approved the use of human tissue. The procedures and handling of tissues exposed to recombinant adenovirus were approved by the Institutional Biosafety Committee of the Mayo Foundation in compliance with the Guidelines for Research Involving Recombinant DNA Molecules published by the National Institutes of Health (NIH Publication No. 59FR34496, amended 1995).
Unused segments of SV, IMA, and RA were obtained from 28 patients undergoing coronary artery bypass grafting; pairing of tissues was not possible. All the specimens had the usual surgical preparation in an attempt to duplicate a clinical correlate with the in vitro studies. Veins were harvested by sharp dissection and suture ligature of side branches via an extended lower extremity incision. RAs were harvested with sharp dissection and surgical clip ligature of side branches. Electrocautery was used for IMA dissection, with surgical clips for branches. At the completion of the anastomosis, the unused portions of bypass grafts were immediately immersed in cold (4°C) tissue culture medium (Rosewell Park Memorial Institute [RPMI] 1640 with HEPES buffer, 20 mmol/L, pH 7.4) containing 10% fetal calf serum, 100 U/mL (final) penicillin, and 100 U/mL (final) streptomycin.
A representative section from each specimen was evaluated by trypan blue exclusion to determine endothelial cell viability. Sections were incubated at room temperature in 0.01% trypan blue in Dulbecco’s phosphate-buffered saline for 1 minute. All specimens demonstrated <10% endothelial disruption; thus, no specimens were discarded.
Organ Culture
Graft segments were sharply dissected in a laminar flow
hood to remove any remaining connective tissue. The grafts were incised
so the luminal surface was exposed and divided into 1-cm lengths. The
segments were cultured by a modification of the method described by
Pederson and Bowyer.7 Vessels were divided into matched
specimens; each portion was then mounted (with the adventitial surface
adjacent to P500 polyester cloth) to sterile Sylgard resin (Dow
Corning) with minute pins. After fixation, the specimens were
immediately overlaid with 6 mL of a culture medium of the following
composition: RPMI 1640 medium containing 2 g/L sodium bicarbonate, 30%
(v/v) fetal bovine serum, 100 U/mL (final) penicillin, 100 U/mL (final)
streptomycin, and 0.8 mmol/L L-glutamine
(temperature, 37°C; pH 7.4).
Cultures were performed in a humidified, 5% CO2 incubator at 37°C (Forma Scientific, Inc). The culture medium was aspirated under sterile conditions and replaced every other morning. The same lot of fetal bovine serum was used for the entire study.
Histologic Examination
Segments were removed from the organ culture, fixed in buffered
formalin, embedded in paraffin, and cut transversely into 3-µm-thick
sections, which were stained with Verhoeff–van Gieson stain for
elastic fibers. The areas of the intima and media were averaged over
the entire length of each specimen using an image analysis
system consisting of a microscope (Nikon, OPTIPHOT-2) with a
solid-state 3 charge-coupled device color video camera mounted
on the phototube. The video signal underwent 24-bit digitalization by a
video frame grabber. The signal was then digitized using a Scion color
digitizer board incorporated in an ImagePro Plus image analysis
system. Color images were stored and analyzed as 24-bit files
with 640 (horizontal) and 480 (vertical) pixel resolution.
Separate samples were snap-frozen (-70°C) in OCT compound, and 5-µm-thick sections were stained for eNOS and proliferating nuclear cell antigen, as previously described.8 The number of positively stained cells was counted with standard light microscopy and normalized to the product of the intimal and medial areas for the entire specimen.
Gene Transfer
Paired human SVs were randomly assigned to 3 groups. The first
group was placed in phosphate-buffered saline with 0.1%
albumin (PBSA, dilution vehicle) alone. The second group was
exposed to recombinant adenovirus-encoding Escherichia coli
ß-galactosidase (Ad.CMVLacZ) for 1 hour at 37°C, as previously
described.9 The third group was exposed to
adenovirus-encoding bovine eNOS (Ad.CMVeNOS) at the same titer. The
vein segments were incised so the luminal surface was exposed; they
were then divided into 1-cm lengths. The segments were cultured as
described above.
Data Analysis
Results are expressed as mean±SEM. In all experiments, n is the
number of patients from whom vessels were taken. Vessels incubated for
each period were obtained from the same patient; analyses
between incubation durations used the 2-way t test for
paired samples. The SV, IMA, and RA samples were obtained from
different patients, and analysis between graft types used the
2-way t test for unpaired samples. SVs exposed to
recombinant adenoviruses were obtained from the same patients and,
thus, analysis used the 2-way t test for paired
samples. Values of P<0.05 were considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Mean intimal and medial thicknesses of human SVs before culture were 36.5±12.4 and 310.0±32.4 µm, respectively; mean intimal and medial thicknesses of human IMAs before culture were 13.2±3.8 and 137.5±36.4 µm, respectively; and mean intimal and medial thicknesses of human RAs before culture were 16.9±7.0 and 213.1±73.7 µm, respectively. The control intima-to-media (I/M) ratios for SVs, IMAs, and RAs were 0.12±0.04, 0.09±0.01, and 0.07±0.01, respectively.
Intimal Hyperplasia With Organ Culture
Human SVs demonstrated progressively greater I/M ratios with
extended culture, which were first significant after 10 days (Figure 1
). The control I/M ratio of SV segments
was 0.12±0.04, and this increased to 0.28±0.05 after 10 days
(P=0.03) and to 0.36±0.11 after 14 days
(P=0.04). In contrast, after 14 days, the IMA I/M ratio
increased to only 0.15±0.04 (P=0.20 versus control) and the
RA I/M ratio, to 0.09±0.01 (P=0.15 versus control).
|
Previous studies suggested that the resulting intimal hyperplasia in extended organ culture is derived predominantly from the cut edges.10 The I/M ratios reported above represent the composite average of the entire specimen to eliminate sampling error. A subgroup analysis was performed of the I/M ratios within 1 optical field of the cut surface and the sample middle. For 7-day culture of SVs, the cut (0.25±0.05) and middle (0.22±0.10) I/M ratios were similar (P=0.96); these ratios were not significantly different (0.43±0.10 versus 0.67±0.23; P=0.65) at 14 days. Although some specimens had greater intimal hyperplasia at the cut surface, the subgroup analysis did not support the hypothesis of predominant growth in this region.
Adenoviral-Mediated Gene Transfer and Intimal Hyperplasia
Initial studies (n=6) were performed at a viral titer of
1010 plaque-forming units per milliliter
(pfu/mL). After 14 days of incubation, intimal hyperplasia was reduced
in Ad.CMVeNOS veins compared with PBSA controls. However, a
concomitant reduction occurred in the I/M ratio of Ad.CMVLacZ veins,
suggesting that overexpression of a recombinant gene indiscriminately
reduced intimal hyperplasia in human SV. Vehicle PBSA controls had an
I/M ratio of 0.20±0.08 at 7 days and 0.30±0.07 at 14 days. Viral
Ad.CMVLacZ controls had an I/M ratio of 0.12±0.03 at 7 days and
0.15±0.04 at 14 days, and the ratio for Ad.CMVeNOS veins was
0.11±0.04 at 7 days and 0.13±0.02 at 14 days.
Therefore, additional studies (n=7) were performed at a lower viral
titer (109 pfu/mL). Vehicle PBSA controls had an
I/M ratio of 0.23±0.06 at 7 days of incubation and 0.39±0.09 at 14
days (Figure 2), and the ratio for viral
Ad.CMVLacZ controls was 0.24±0.09 at 7 days and 0.30±0.03 at 14 days.
The difference between vehicle and viral controls for either period of
incubation was not significant (P=0.95 and 0.13,
respectively). Human SVs exposed to Ad.CMVeNOS had an I/M ratio of
0.22±0.10 at 7 days of incubation (P=0.85 versus PBSA and
P=0.83 versus Ad.CMVLacZ). However, the I/M ratio of eNOS
veins decreased to 0.13±0.06 after 14 days (P=0.001 versus
PBSA and P=0.004 versus Ad.CMVLacZ).
|
Immunohistochemical studies with a monoclonal antibody specific for eNOS demonstrated discrete, high-level expression of eNOS in the endothelium and adventitia of Ad.CMVeNOS veins, which was similar to the findings in previous reports.8 Minimal eNOS immunostaining was noted in PBSA and Ad.CMVLacZ veins, which correlated with the known low-level endothelial expression.
Immunohistochemical studies for proliferating nuclear cell antigen and Ki67 demonstrated low-level expression of each proliferation index after extended organ culture. This correlates with the results of previous reports.11
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The major findings of the present study are that (1) the human SV, but not the IMA, generates intimal hyperplasia during extended organ culture; (2) the human RA does not produce significant intimal hyperplasia during extended organ culture; and (3) adenoviral-mediated gene transfer of eNOS inhibits intimal hyperplasia in the human SV.
The original study of extended organ culture used rabbit aortas to examine the endothelial response to injury.7 This model consistently produces neointimal overgrowth by smooth muscle cell migration,12 and it is devoid of fibroblast contamination.10 Intimal proliferation of human SV in organ culture is dependent on surgical preparation,13 production of vasoactive substances,14 15 16 and presence of growth factors.11 17 The advantages of this preparation include the manner in which human vessels can be maintained in controlled and reproducible conditions to analyze specific interventions. Human tissue can be manipulated ex vivo in a manner that would require animal studies for an in vivo setting.
However, as with all models, limitations exist. Although the human tissue underwent the usual surgical manipulation, the preparation does not duplicate the clinical setting because the system is without immunologic, cytokine, and hemodynamic influences. Despite these shortcomings, the model seems to be a good alternative to in vivo studies.
The specimens harvested in the present study correlate well with previously published morphometric data. The mean intimal and medial thicknesses of SV were similar to the 100 consecutive veins examined by Varty et al.18 The greater wall thickness in RAs than in IMAs correlated well with the results of van Son et al,19 except that the RA specimens in our series showed less of a differential.
RA Grafts
Reasonable early and midterm patency rates have been reported
recently for RA grafts. Rates have ranged from 87.8% to 95.7% during
the first 18 months. The reported 5-year patency rates range from 83%
to 92%. Although these values are favorable compared with those for
saphenous vein grafts, skepticism is still justified on the basis of
the earlier history of RA grafts.20
Although areas of preexisting disease have previously been noted,21 the average I/M ratio of RAs in our study was not different from that of other grafts. Organ culture of up to 14 days was not associated with significant intimal hyperplasia. This is in contrast to the behavior of SVs; the I/M ratio in veins nearly tripled during the same duration of incubation. The behavior of the RA in the current study, which was similar to that of the IMA, supports the continued, cautious, clinical use of this conduit.
Gene Therapy for SV Graft Disease
Neointimal hyperplasia is the ubiquitous response of
the vasculature to injury; it results in a lesion that can be
flow-limiting and consists of secretory vascular smooth muscle cells
and extracellular matrix. The pathophysiology of neointimal
hyperplasia after vascular injury has been studied extensively. In
brief, endothelial injury and denudation permit
platelet adhesion and aggregation during harvest or surgical
exposure. The adherence of platelets to the
endothelial surface is also likely due to decreased
production of prostacyclin and nitric oxide concomitant with
endothelial dysfunction.22 This is
followed by stimulation of vascular smooth muscle cells to proliferate
and to migrate to the intima. The smooth muscle cells undergo a
phenotypic change, from contractile to secretory cells, and
extracellular matrix accumulates. Platelet activation provokes the
release of platelet-derived growth factor and basic fibroblast
growth factor. Both factors, present in the fetal calf serum used
for our culture preparation, stimulate the migration of vascular smooth
muscle cells from the media into the intima and the synthesis of
extracellular matrix, collagen, and proteoglycans.23
Our preparation of human SVs consistently produced intimal hyperplasia during 2 weeks of culture. The viral LacZ controls had a slightly less robust intimal hyperplasia than vehicle controls. Newman et al24 noted that intimal hyperplasia was markedly stimulated with an adenoviral vector encoding for LacZ in rabbit arteries. However, it seems that gene therapy elicits an immunologic response to either transgene expression or low-level viral protein expression on the cell membrane.25 In extended organ culture, no immunologic response was permitted; the culture media was acellular. Therefore, an intriguing suggestion from the present study is that highly promoted overexpression of a transgene, in and of itself, may tend to inhibit intimal hyperplasia.
Augmented nitric oxide levels inhibit the intimal hyperplasia of grafts. Von der Leyen et al26 first demonstrated that gene transfer of eNOS inhibited intimal thickening in rat carotid arteries after angioplasty. Immunohistochemical examination demonstrated increased expression of eNOS with adenoviral-mediated gene transfer; this is similar to findings we have reported previously in animal and human tissue.8 9 27 That eNOS overexpression inhibited SV hyperplasia is not entirely unexpected. Soyombo et al16 demonstrated that the 8-bromocyclic guanosine monophosphate analogue inhibited SV neointimal hyperplasia by 40%. What is remarkable is that the I/M ratio was similar for all groups at 7 days of culture. It was not until after 14 days that a significant difference was observed between the groups. This may be explained partly by the kinetics of guanosine triphosphate during organ culture.15 Nitric oxide stimulates the conversion of guanosine triphosphate to cyclic guanosine monophosphate by guanylate cyclase. Immediately after surgical preparation, the level of guanosine triphosphate decreases significantly and slowly begins to increase during the subsequent 14 days of incubation.
Recently, others have demonstrated reduced intimal hyperplasia in human SV in organ culture with gene therapy.28 Adenovirus-mediated gene transfer of the tissue inhibitor metalloproteinase 1 inhibited neointimal formation by 54% and smooth muscle cell migration by 78%. The viability of human SV in extended organ culture after exposure to the current generation of adenoviral vectors supports the role of this model in preclinical testing of coronary artery bypass conduits.
Gene therapy has attracted attention for its potential to treat several cardiovascular disease processes. However, adenoviral vectors can elicit an immunologic response as a result of a viral product or transgene expression, and this immunologic response may increase the intimal hyperplastic reaction above baseline levels. Despite these possible deficiencies, gene therapy may be useful in the prevention of coronary artery bypass graft disease.
|
Acknowledgments |
|---|
Supported in part by the Mayo Foundation. Performed during the tenure of D.G.C. as a Clinical Investigator Research Fellow.
|
Footnotes |
|---|
Reprint requests to Hartzell V. Schaff, MD, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.
Guest editor for this article was James T. Willerson, MD, St. Luke’s Episcopal Hospital/Texas Heart Institute, Houston.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
-
Loop FD, Lytle BW, Cosgrove DM, Stewart RW,
Goormastic M, Williams GW, Golding LA, Gill CC, Taylor PC, Sheldon WC,
Proudfit WL. Influence of the internal-mammary-artery graft on 10-year
survival and other cardiac events. N Engl J
Med. 1986;314:1–6.[Abstract]
-
Acar C, Jebara VA, Portoghese M, Beyssen B, Pagny JY,
Grare P, Chachques JC, Fabiani JN, Deloche A, Guermonprez JL,
Carpentier AF. Revival of the radial artery for coronary artery
bypass grafting. Ann Thorac Surg. 1992;54:652–659.[Abstract]
-
FitzGibbon GM, Leach AJ, Keon WJ, Burton JR,
Kafka HP. Coronary bypass graft fate. Angiographic study of
1,179 vein grafts early, 1 year, and 5 years after operation.
J Thorac Cardiovasc Surg. 1986;91:773–778.[Abstract]
-
Grondin CM, Campeau L, Lesperance J, Solymoss BC,
Vouhe P, Castonguay YR, Meere C, Bourassa MG. Atherosclerotic
changes in coronary vein grafts 6 years after operation:
angiographic aspect in 110 patients. J Thorac Cardiovasc
Surg. 1979;77:24–31.[Medline]
[Order article via Infotrieve]
-
Weintraub WS, Jones EL, Craver JM, Guyton RA.
Frequency of repeat coronary bypass or coronary
angioplasty after coronary artery bypass surgery using
saphenous venous grafts. Am J Cardiol. 1994;73:103–112.[Medline]
[Order article via Infotrieve]
-
Akins CW, Buckley MJ, Daggett WM, Hilgenberg AD,
Vlahakes GJ, Torchiana DF, Austen WG. Reoperative coronary
grafting: changing patient profiles, operative indications, techniques,
and results. Ann Thorac Surg. 1994;58:359–364.[Abstract]
-
Pederson DC, Bowyer DE.
Endothelial injury and healing in vitro. Studies using
an organ culture system. Am J Pathol. 1985;119:264–272.[Abstract]
-
Cable DG, O’Brien T, Schaff HV, Pompili VJ.
Recombinant endothelial nitric oxide
synthase-transduced human saphenous veins: gene therapy to augment
nitric oxide production in bypass conduits.
Circulation. 1997;96(suppl II):II-173–II-178.
-
Cable DG, O’Brien T, Kullo IJ, Schwartz RS, Schaff
HV, Pompili VJ. Expression and function of a recombinant
endothelial nitric oxide synthase gene in porcine
coronary arteries. Cardiovasc Res. 1997;35:553–559.
[Abstract/Free Full Text]
-
Slomp J, Gittenberger-deGroot AC, van Munsteren JC,
Huysmans HA, van Bockel JH, van Hinsbergh VW, Poelmann RE. Nature and
origin of the neointima in whole vessel wall organ culture
of the human saphenous vein. Virchows Arch. 1996;428:59–67.[Medline]
[Order article via Infotrieve]
-
Porter KE, Varty K, Jones L, Bell PR, London NJ. Human
saphenous vein organ culture: a useful model of intimal hyperplasia?
Eur J Vasc Endovasc Surg. 1996;11:48–58.[Medline]
[Order article via Infotrieve]
-
Soyombo AA, Angelini GD, Bryan AJ, Jasani B, Newby AC.
Intimal proliferation in an organ culture of human saphenous vein.
Am J Pathol. 1990;137:1401–1410.[Abstract]
-
Holt CM, Francis SE, Newby AC, Rogers S, Gadsdon PA,
Taylor T, Angelini GD. Comparison of response to injury in organ
culture of human saphenous vein and internal mammary artery. Ann
Thorac Surg. 1993;55:1522–1528.
-
Masood I, Porter KE, London NJ. Endothelin-1 is a
mediator of intimal hyperplasia in organ culture of human saphenous
vein. Br J Surg. 1997;84:499–503.[Medline]
[Order article via Infotrieve]
-
Jeremy JY, Birkett SD, Bryan AJ, Angelini GD. The
influence of surgical preparation on cyclic nucleotide
synthesis in an organ culture of human saphenous vein. Eur J Vasc
Endovasc Surg. 1997;13:72–78.[Medline]
[Order article via Infotrieve]
-
Soyombo AA, Angelini GD, Newby AC.
Neointima formation is promoted by surgical preparation and
inhibited by cyclic nucleotides in human saphenous vein
organ cultures. J Thorac Cardiovasc Surg. 1995;109:2–12.
[Abstract/Free Full Text]
-
Allen KE, Varty K, Jones L, Sayers RD, Bell PR, London
NJ. Human venous endothelium can promote intimal
hyperplasia in a paracrine manner. J Vasc Surg. 1994;19:577–584.[Medline]
[Order article via Infotrieve]
-
Varty K, Porter K, Bell PR, London NJ. Vein morphology
and bypass graft stenosis. Br J Surg. 1996;83:1375–1379.[Medline]
[Order article via Infotrieve]
-
van Son JA, Smedts F, Vincent JG, van Lier HJ, Kubat K.
Comparative anatomic studies of various arterial conduits
for myocardial revascularization. J
Thorac Cardiovasc Surg. 1990;99:703–707.[Abstract]
-
Curtis JJ, Stoney WS, Alford WC Jr, Burrus GR,
Thomas CS Jr. Intimal hyperplasia: a cause of radial artery
aortocoronary bypass graft failure. Ann Thorac Surg. 1975;20:628–635.[Abstract]
-
Kaufer E, Factor SM, Frame R, Brodman RF. Pathology of
the radial and internal thoracic arteries used as coronary
artery bypass grafts. Ann Thorac Surg. 1997;63:1118–1122.
[Abstract/Free Full Text]
-
Angelini GD, Breckenridge IM, Psaila JV, Williams HM,
Henderson AH, Newby AC. Preparation of human saphenous vein for
coronary artery bypass grafting impairs its capacity to produce
prostacyclin. Cardiovasc Res. 1987;21:28–33.[Medline]
[Order article via Infotrieve]
-
LoGerfo FW, Quist WC, Cantelmo NL, Haudenschild CC.
Integrity of vein grafts as a function of initial intimal and medial
preservation. Circulation. 1983;68(suppl II):II-117–II-124.
-
Newman KD, Dunn PF, Owens JW, Schulick AH, Virmani R,
Sukhova G, Libby P, Dichek DA. Adenovirus-mediated gene transfer into
normal rabbit arteries results in prolonged vascular cell activation,
inflammation, and neointimal hyperplasia. J Clin
Invest. 1995;96:2955–2965.
-
McCray PB Jr, Armstrong K, Zabner J, Miller DW,
Koretzky GA, Couture L, Robillard JE, Smith AE, Welsh MJ.
Adenoviral-mediated gene transfer to fetal pulmonary epithelia
in vitro and in vivo. J Clin Invest. 1995;95:2620–2632.
-
von der Leyen HE, Gibbons GH, Morishita R, Lewis NP,
Zhang L, Nakajima M, Kaneda Y, Cooke JP, Dzau VJ. Gene therapy
inhibiting neointimal vascular lesion: in vivo transfer of
endothelial cell nitric oxide synthase gene. Proc
Natl Acad Sci U S A. 1995;92:1137–1141.
[Abstract/Free Full Text]
-
Cable DG, Caccitolo JA, Pearson PJ,
O’Brien T, Mullany CJ, Daly RC, Orszulak TA, Schaff HV. New approaches
to prevention and treatment of radial artery graft vasospasm.
Circulation. 1998;98(suppl II):II-15–II-21.
-
George SJ, Johnson JL, Angelini GD, Newby AC, Baker AH.
Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits
smooth muscle cell migration and neointimal formation in
human saphenous vein. Hum Gene Ther. 1998;9:867–877.[Medline]
[Order article via Infotrieve]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||